FDA, EMA and Infarmed GMP Guidance and Warning Letters
Official GMP regulatory sample refreshed 19 November 2026: 416 records covering FDA warning letters and guidance, EMA GMP/GDP guidance, EudraLex Volume 4 references, Infarmed…

paulh
@Jason build this dataset: gMP guidance and warning letters from FDA, EMA, EudraLex and Infarmed, with document dates, source links and change-comparison fields. The published dataset contains 416 document records. Refreshed on demand.

JasonApp
On it. Reading
europa.eu
infarmed.pt
fda.gov.

JasonApp
416 documents, 27 columns in this dataset.
416 documents, refreshed on demand
3 data sources so far
Sample · 50 rows
You’re viewing a sample of this dataset.
| Row# | Open row | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Infarmed | 2026-11-19 | First observation of this document | New | — | 843e736f04c01e13064d92fb00eda3246a9e59cbea4c4289ffa768c79232d2fb | SHA-256 of complete PDF bytes | 2026-11-13 | Circular issue date | Infarmed:104/CD/550.20.001:2026 | Circular: restriction lifted | Infarmed | — | Limeciclina Atral 408 mg Capsula Levantamento de Suspensao da AIM | 2026-11-18 | 1.0 | Publication date is the official index posting date; date is the circular issue date. | "Limeciclina Atral 408 mg Cápsula - Levantamento de Suspensão da AIM" | Limeciclina Atral 408 mg Capsula Levantamento de Suspensao da AIM | false | View row | ||||||
| 2 | FDA | 2026-11-19 | First observation of this document | New | Natural Essentials, Inc. | d22492342afddfbc8e0e0a6ff3ab6287f7ea70d3133f8cd2d37e88a90ca9bb3d | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-10 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-17 | — | — | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Natural Essentials, Inc. - GMP warning letter | false | View row | ||||||
| 3 | FDA | 2026-11-19 | First observation of this document | New | Umicore Argentina S.A. | be7ed044ef54dfaab2e685c70c2c2d1d55d3cb684572d227ce45c34c8c9d6fd1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-06 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | 2026-11-17 | — | — | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | Umicore Argentina S.A. - GMP warning letter | false | View row | ||||||
| 4 | FDA | 2026-11-19 | First observation of this document | New | Shenzhen Benliju Biotech Co., Ltd. | af0def15b7700768792e835078342368d6c55d2cc4eaf8fec625e75d071d0bb1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-06 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-17 | — | — | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | Shenzhen Benliju Biotech Co., Ltd. - GMP warning letter | false | View row | ||||||
| 5 | FDA | 2026-11-19 | First observation of this document | New | Nanjing Hanxin Pharmaceutical Technology Co. Ltd. | 4a47f6fe5763d608d3663b83ab2ae19e7cec60d396330f295b925619d9bcc398 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-03 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-10 | Request for Records/CGMP/API/Adulterated | 2026-11-10 | — | — | Request for Records/CGMP/API/Adulterated | Nanjing Hanxin Pharmaceutical Technology Co. Ltd. - GMP warning letter | false | View row | ||||||
| 6 | FDA | 2026-11-19 | First observation of this document | New | USV Private Limited | 9b7cbe7a859f3d2104429fcf896257494f4f3542f89efbf671ef8e0fa7bd3886 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-02 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-10 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-11-10 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | USV Private Limited - GMP warning letter | false | View row | ||||||
| 7 | FDA | 2026-11-19 | First observation of this document | New | LGM Pharma Solutions, LLC | 14d8f50864a15dd411719912bf93b7926ed768cf176dac5648a9b20602d8ccb1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-02 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-11-17 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | LGM Pharma Solutions, LLC - GMP warning letter | false | View row | ||||||
| 8 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | — | 336760c2b75c7e9d533e7287dcabe87c17d0991431d57d7e0edc165d05ee2793 | SHA-256 of complete PDF bytes | 2026-11-02 | Guidance issue date | Guidance (final) | 2026-11-09 | Center for Biologics Evaluation and Research | 2026-11-02 | Gene Therapy | 2026-11-02 | — | — | Final guidance; Gene Therapy | Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products | false | View row | ||||||
| 9 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Conroe Welding Supply, Inc. | 4ecc729857b41ff664865433d884c2ea072368ebbf99031296e3b7d1cf9ad594 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-29 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | CGMP/Medical Gases/Adulterated | 2026-11-03 | — | — | CGMP/Medical Gases/Adulterated | Conroe Welding Supply, Inc. - GMP warning letter | false | View row | |||||
| 10 | FDA | 2026-11-19 | First observation of this document | New | Chongqing Qiancan Technology Co., Ltd. | 0d66f22f0e6c01c926a88cef7a523db194c547033a5ec24ff832372ac74d8cec | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-29 | Letter issue date | — | Warning letter | Center for Drug Evaluation and Research (CDER) | 2026-11-10 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | 2026-11-10 | — | — | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | Chongqing Qiancan Technology Co., Ltd. - GMP warning letter | false | View row | ||||||
| 11 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Pritam International Private Limited | 9e9cdb3849dc53058b67ec8ad4f5bfea6755550494e4a3c3b1388d18d8accdeb | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-27 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-11-03 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Pritam International Private Limited - GMP warning letter | false | View row | |||||
| 12 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Guangzhou Jiugong Research And Development Biotechnology Co., Ltd. | 9b99374ca254dd2a0192c2fd7fdc4d51dda59e403196f2b65a5d2474747d872a | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-27 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-03 | — | — | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Guangzhou Jiugong Research And Development Biotechnology Co., Ltd. - GMP warning letter | false | View row | |||||
| 13 | Infarmed | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | — | 701b016c2a1cb2cb3b774a10565309be0d93c2c74aafdb7f3d7e44c162914ff7 | SHA-256 of complete PDF bytes | 2026-10-26 | Circular issue date | Infarmed:097/CD/550.20.001:2026 | Recall circular | 2026-11-09 | Infarmed | — | Recolha do medicamento Besilato de Atracúrio Basi, 10 mg ml, Solução injetável - lote n.º P0092, validade 01 2027 | 2026-11-04 | 1.0 | Publication date is the official index posting date; date is the circular issue date. | por ter sido detetado potencial contaminação e contaminação cruzada. | Recolha do medicamento Besilato de Atracúrio Basi, 10 mg ml, Solução injetável - lote n.º P0092, validade 01 2027 | false | View row | |||||
| 14 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Guangdong Bangze Medicine Co., Ltd. | 25acc1a90178ad0b4406456826cb93791bc3bd126c58a2585f706f21a14bff56 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-26 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-03 | — | — | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Guangdong Bangze Medicine Co., Ltd. - GMP warning letter | false | View row | |||||
| 15 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | TSP Solutions Pte. Ltd. | f83dc2813a5dc790bfd721e38f102bab2f75e66c26666f6ec344cbaffea38cc2 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-22 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-27 | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-10-27 | — | — | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | TSP Solutions Pte. Ltd. - GMP warning letter | false | View row | |||||
| 16 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Sanrace Biotechnology Co., Ltd. | 70b35f2a5df9dadd55362c72293475acdf70133eb034d2cfcad117d6836320e3 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-22 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-27 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-27 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Sanrace Biotechnology Co., Ltd. - GMP warning letter | false | View row | |||||
| 17 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Northland Nuclear Medicine, LLC | e81fed15b67a6d7062241bb691916b5aaf6e101034ea62c63e29d59436c986db | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-22 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-27 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-27 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Northland Nuclear Medicine, LLC - GMP warning letter | false | View row | |||||
| 18 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Bausch & Lomb Inc. | 6e0a2c824803440e26d3d0d8738582945bdc62dc74e5b4d2917476910c63ba87 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-04 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-15 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-15 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Bausch & Lomb Inc. - GMP warning letter | false | View row | |||||
| 19 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Glukem Biocare Private Limited | 5c641ff22fe5539a2e9baa1157b2de76bbece01801d70db242ec8529df333ac8 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-16 | Report issue date | GMP non-compliance report | 2026-11-09 | Malta Medicines Authority | — | 1.2 Non-sterile products 1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.17 Other: Manufacture of intermediates (pellets)(en) 1.6 Quality control testing 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical | 2026-10-16 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The inspection resulted in a critical deficiency related to contamination risk in the Fluid Bed Coating (FBC) equipment due to an observed pool of liquid and residue in a section of the inlet air plenum of a fully cleaned FBC. The flaws were due to common design between FBCs (inclination of plenum not allowing gravity draining) and inadequate cleaning procedure. In addition, there was no detectability of a failure in HEPA filter integrity through real-time monitoring of pressure differential before and after the supply air HEPA filter of the Air Handling Units of the FBCs. There were eleven (11) major findings relating to: Inadequate Master Batch Record instructions and production documentation; Deficient process validation, including insufficient coverage of process, demonstration of its reproducibility and pellet homogeneity; Incomplete cleaning validation; Differential pressure excursions; Deficient warehouse, sampling and dispensing controls; Inadequate vendor qualification; Inadequate identification testing of incoming starting materials, Excipient risk assessments, Out-of-Specification handling, Equipment qualification and Pest control. | MT/004NCR/2026 - Glukem Biocare Private Limited | false | View row | ||||||
| 20 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Rohto Pharmaceutical Co., Ltd. | 73ce1ceb50da453ec2cff67b2bfd194bf1f0eed36ac4c54bbb8085fd030fa510 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-14 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated/OTC | 2026-10-20 | — | — | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated/OTC | Rohto Pharmaceutical Co., Ltd. - GMP warning letter | false | View row | |||||
| 21 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | — | ec163d276b071f94604724d9fa362f0b13f7bb266b02eb46526683c87a7a329a | SHA-256 of complete PDF bytes | 2026-10-09 | Guidance issue date | Guidance (final) | 2026-11-09 | Center for Drug Evaluation and Research | 2026-10-13 | Biosimilars | 2026-10-09 | — | — | Final guidance; Biosimilars | Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers | false | View row | ||||||
| 22 | EMA / EudraGMDP | 2026-11-19 | First observation of this document | New | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 61a5e2c6a1d42787fa249fe907248f53609ac715cd28c07fbb336d6cbe9b0945 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-08 | Report issue date | GMP non-compliance report | Health And Youth Care Inspectorate | — | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2 Lyophilisates 1.1.1.4 Small volume liquids 1.1.1.6 Other: cell therapy products and gene therapy products(en) 1.2 Non-sterile products 1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.1 Capsules, hard shell 1.2.1.13 Tablets 1.3 Biological medicinal products (list of product types) 1.3.1 Biological medicinal products (list of product types) 1.3.1.3 Cell therapy products 1.3.1.4 Gene therapy products 1.3.1.5 Biotechnology products 1.5 Packaging 1.5.1 Primary Packaging 1.5.1.1 Capsules, hard shell 1.5.1.13 Tablets 1.5.2 Secondary packaging Clarifying remarks (for public users): Activities restricted to the location Louwesweg 6 in Amsterdam. | 2026-10-08 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials). | NL/H 26/2008484B - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | View row | |||||||
| 23 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 7f05863b911dbbce73e2a3f67638c5ffb5285c28e7e439a601e4d32649d7c719 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-07 | Report issue date | GMP non-compliance report | 2026-11-09 | Health And Youth Care Inspectorate | — | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.6 Other: cell therapy products and gene therapy products(en) 1.1.3 Batch certification 1.2 Non-sterile products 1.2.2 Batch certification 1.3 Biological medicinal products (list of product types) 1.3.1 Biological medicinal products (list of product types) 1.3.1.3 Cell therapy products Special Requirements: 3 Live Cells 1.3.1.4 Gene therapy products Special Requirements: 3 Live Cells 1.3.1.5 Biotechnology products Special Requirements: 3 Live Cells 1.3.2 Batch Certification (list of product types) 1.3.2.3 Cell therapy products 1.3.2.4 Gene therapy products 1.3.2.5 Biotechnology products 1.5 Packaging 1.5.2 Secondary packaging 1.6 Quality control testing 1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical 1.6.4 Biological Clarifying remarks (for public users): ad 1.1.3 and 1.2.2: Batch certification of human investigational medicinal products, prepared at location :Louwesweg 6 as well as location Plesmanlaan 121 in Amsterdam is performed at location Plesmanlaan 121 in Amsterdam; ad 1.6.4 concerns endotoxin tests and flowcytometry. | 2026-10-07 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials). | NL/H 26/2008484D - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | View row | ||||||
| 24 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 21d12a7e6d07b27146b8d74c7c648cbe1b1c71fc5ad7daedefe5080ac5aa62ca | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-07 | Report issue date | GMP non-compliance report | 2026-11-09 | Health And Youth Care Inspectorate | — | 1.1 Sterile products 1.1.3 Batch certification 1.2 Non-sterile products 1.2.2 Batch certification 1.6 Quality control testing 1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical 1.6.4 Biological Clarifying remarks (for public users): ad 1.1.3 and 1.2.2: Batch certification of human related products prepared at location Louwesweg 6 in Amsterdam, is performed at location Plesmanlaan 121 in Amsterdam; ad 1.1.3 batch certification (lyophilisates); ad 1.2.2 batch certification (other solods dosage forms); af 1.6.4 concerns endotoxin tests. | 2026-10-07 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials). | NL/H 26/2008484C - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | View row | ||||||
| 25 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 0c7884ef52dfa4396f7e7bdbd22121c9526f636133ce213cf734fbbbf38fbb91 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-07 | Report issue date | GMP non-compliance report | 2026-11-09 | Health And Youth Care Inspectorate | — | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2 Lyophilisates 1.2 Non-sterile products 1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.8 Other solid dosage forms 1.5 Packaging 1.5.1 Primary Packaging 1.5.1.8 Other solid dosage forms 1.5.2 Secondary packaging Clarifying remarks (for public users): Activities restricted to the location Louwesweg 6 in Amsterdam. | 2026-10-07 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials). | NL/H 26/2008484A - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | View row | ||||||
| 26 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Eurofins SF Analytical Laboratories, Inc. | 576b4707da31402ebd35a1fdee9b423f307a128c6434bbb534ed82be4be4f0a6 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-06 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-13 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Eurofins SF Analytical Laboratories, Inc. - GMP warning letter | false | View row | |||||
| 27 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Silgan Dispensing Systems | 8ea2906f44040f50280456f74d265ef8d92a30c3dd4e18ad46f0e3b15093b8fa | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-05 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/OTC | 2026-10-13 | — | — | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/OTC | Silgan Dispensing Systems - GMP warning letter | false | View row | |||||
| 28 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Hanlim Pharm Co., Ltd. | 3fb0d9b6514ad99c40ad712eb45d2bb052621d72ec1dae9724420771b108d513 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-02 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-13 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Hanlim Pharm Co., Ltd. - GMP warning letter | false | View row | |||||
| 29 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Zhejiang Gaorong Cosmetic Co., Ltd. | d5e34296fc9dbac5fcc6e439a663a2127fae21592079332254ea0b227cb48387 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-01 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Zhejiang Gaorong Cosmetic Co., Ltd. - GMP warning letter | false | View row | |||||
| 30 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Signature Formulations LLC | 31172b18651386d85ce560295d8b7a303f640ea509a172699824c9df962a8528 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-01 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Signature Formulations LLC - GMP warning letter | false | View row | |||||
| 31 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Baxter International Inc. | 3d8ba70c46fdf22b5211ab4a7aff10be676bfb613584beb6a37a033a2b8e8187 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-29 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Baxter International Inc. - GMP warning letter | false | View row | |||||
| 32 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | SnugZ USA, Inc. | af261fc4a26df5dbc6c04d9dc60c493223acb0aaeec6963d66829c75a443ecd4 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-28 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | SnugZ USA, Inc. - GMP warning letter | false | View row | |||||
| 33 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Ocb Pharmaceutical S.R.L. | c40897cf2bcd5215e2f245a71be0b99b155d07c2a86c55c007f51c54a816a263 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-28 | Report issue date | GMP non-compliance report | 2026-11-09 | Spanish Agency Of Medicines And Medical Devices | — | 1.4 Other products or manufacturing activity 1.4.1 Manufacture of 1.4.1.3 Other: Manufacturing of active substances(en) Manufacture of active substance. Names of substances subject to non-compliant: BISMUTH CITRATE(en) [2187WR]BISMUTH SUBCITRATE COLLOIDAL(en) [90105A]BISMUTH SUBGALLATE(en) [90773A]BISMUTH SUBNITRATE(en) [136BP]BISMUTH SUBSALICYLATE(en) [9087A]SODIUM AND BISMUTH TARTRATE(en) [503TFB]BISMUTH TRIBROMOPHENATE(en) [503OX]BISMUTH OXIDE(en) [503BSC]BISMUTH SUBCARBONATE(en) 3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES Active Substance:BISMUTH CITRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBCITRATE COLLOIDAL 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.5 General Finishing Steps 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBGALLATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling or micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBNITRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBSALICYLATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling or micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:SODIUM AND BISMUTH TARTRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.5 General Finishing Steps 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH TRIBROMOPHENATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH OXIDE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBCARBONATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1 Physical processing steps: drying, milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing | 2026-09-28 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | During the inspection, a total of nine (9) deficiencies were identified, one (1) of them were classified as critical and eight (8) as major. The deficiencies identified demonstrate significant weakness in the pharmaceutical quality system implemented at the site and raise serious concerns regarding the reliability of manufacturing, storage, documentation, cross contamination control, traceability and quality assurance oversight activities. The critical deficiency related to the repackaging, relabelling and distribution of bismuth subsalicylate originating from a Chinese manufacturing operating outside the EU GMP framework. The inspection demonstrated that OCB PHARMACEUTICAL, S.R.L. assigned new batch numbers, issued certificates of analysis containing analytical results copied from supplier documentation, removed or replaced original labels and distributed the material to pharmaceutical costumers without adequately preserving the identity of the original manufacturer and the traceability of the supply chain. These practices gave the material the appearance of being associated with OCB PHARMACEUTICAL, S.R.L. manufacturing activities, not complying with GMP Part II requirements concerning the integrity and traceability of the supply chain. Major deficiencies were identified in the effectiveness of the deviation, investigation, CAPA and risk management system; data integrity controls, personnel qualification and training; material management and traceability; contamination and cross-contamination control measures; maintenance and cleaning of facilities and equipment; documentation practices; and quality system governance. The combination of these deficiencies indicates that the quality management system is not capable of consistently ensuring the manufacture, storage and distribution of active substances in compliance with GMP Part II requirements.Particular concerns were identified regarding the design, maintenance, qualification and operation of HVAC systems and differential pressure controls, recurring environmental monitoring excursions, deficiencies in cleaning practices, uncontrolled access between classified and technical areas, inadequate investigation of contamination events and the lack of effective reassessment of cross-contamination risks following multiple significant quality incidents. These deficiencies may have compromised the effectiveness of controls intended to prevent contamination and cross-contamination of active substances manufactured at the site. In addition, deficiencies in governance and management oversight were observed. The inspection findings demonstrate that quality-related decisions were not always supported by adequate quality risk management principles and the quality unit did not exercise sufficient authority to ensure that manufacturing activities were restricted, suspended or adequately controlled when significant quality concerns were identified. | NCF-II/NC2026/01/CAT - Ocb Pharmaceutical S.R.L. | false | View row | ||||||
| 34 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Jiangmen Shuizirun Sanitary Articles Co., Ltd. | 64f65f7a58759f493878cf8643093fcdd73c4b675271af17ed42ae98155e2303 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-23 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-10-13 | — | — | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Jiangmen Shuizirun Sanitary Articles Co., Ltd. - GMP warning letter | false | View row | |||||
| 35 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Fresenius Kabi USA LLC | 2e5048b6b3ca078fae32ff37e632d2dd23b1762816d94f86fd7999cc354e72ec | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-22 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-29 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Fresenius Kabi USA LLC - GMP warning letter | false | View row | |||||
| 36 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Babikian Healthcare Products CJSC | e079bcb87445474e6d2ec3e358c0cc8c2f25e57dfc324710efa7d7348bb77d43 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-21 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-29 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Babikian Healthcare Products CJSC - GMP warning letter | false | View row | |||||
| 37 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Xi'an Guokang Ruijin Pharmaceutical Co. Ltd. | 61e283eacfb05bf69ca1014ed74712fbd5d6f1a39df14990423ef1abb1ce6d6d | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-21 | Report issue date | GMP non-compliance report | 2026-11-09 | Finnish Medicines Agency | — | 1.4 Other products or manufacturing activity 1.4.1 Manufacture of 1.4.1.3 Other: active substance(en) Manufacture of active substance. Names of substances subject to non-compliant: DEXAMETHASONE SODIUM PHOSPHATE(en) BETAMETHASONE(en) DEXAMETHASONE(en) 3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES Active Substance:DEXAMETHASONE SODIUM PHOSPHATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: crystallization 3.5 General Finishing Steps 3.5.1 Physical processing steps: milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:BETAMETHASONE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: crystallization 3.5 General Finishing Steps 3.5.1 Physical processing steps: milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Active Substance:DEXAMETHASONE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: crystallization 3.5 General Finishing Steps 3.5.1 Physical processing steps: milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Clarifying remarks (for public users): Dexamethasone covers crystalline forms A and B | 2026-09-21 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The inspection team identified 18 deficiencies (grouped) against EU GMP, of which 11 were classified as Major. The major deficiencies were related to: Inadequacy of Quality Assurance oversight and Quality management system Inadequate design, poor maintenance/cleaning, lack of contamination control in intermediates manufacturing facilities Solvent recovery, lack of traceability and risk of cross-contamination Risk of supplying non-GMP APIs for production of medicinal products for human or animal use Change control Data integrity of documentation and records Traceability and control of material throughout the manufacturing process Cleaning and process validation Material management Insufficient control of analytical methods Incomplete understanding and incorrect application of fundamental GMP principles | FIMEA/2026/003795 - Xi'an Guokang Ruijin Pharmaceutical Co. Ltd. | false | View row | ||||||
| 38 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Empower Clinic Services, LLC dba Empower Pharmacy | 1a6a9e08e65bebfd99712884f3e6fe1bc24d4f2aa1cb83d6c7517fbdee96140c | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-18 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-22 | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | 2026-09-22 | — | — | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Empower Clinic Services, LLC dba Empower Pharmacy - GMP warning letter | false | View row | |||||
| 39 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Curia New York, Inc. | f6f9277a66dbd51c6968387a96ebdd01887a1a5a002f99f11865e38a1a5f2105 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-18 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | 2026-09-29 | — | — | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | Curia New York, Inc. - GMP warning letter | false | View row | |||||
| 40 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Bentley Laboratories LLC | 89ba8bef67a1798f9e446ba49faab0c97eea62f64c5e08d773abf5347eab9b74 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-17 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated | 2026-09-29 | — | — | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated | Bentley Laboratories LLC - GMP warning letter | false | View row | |||||
| 41 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | — | bd4f2c82ea379c463e3cd034535699654d000191a302bf2723e695c57186ad14 | SHA-256 of complete PDF bytes | 2026-09-16 | Guidance issue date | Guidance (final) | 2026-11-09 | Center for Biologics Evaluation and Research | 2026-09-17 | Blood, Blood Products | 2026-09-16 | — | — | Final guidance; Blood, Blood Products | Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method | false | View row | ||||||
| 42 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | SCA Pharmaceuticals, LLC | e4bebf91f0bb4853fd726bbcb2727a4744c9957e7df5d6c5a96ceb216f129076 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-14 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-13 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | SCA Pharmaceuticals, LLC - GMP warning letter | false | View row | |||||
| 43 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | kdc/one Chatsworth, Inc. | dc3f8cee08bb2e8e1435aec5c4c92780a72543e4ba7d5a831a57be54685f796a | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-08 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-22 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-22 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | kdc/one Chatsworth, Inc. - GMP warning letter | false | View row | |||||
| 44 | EMA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | — | 4130b578aa945eb72531eb6986978681100e28a34dfda5f8e4ccc3bf57cd851e | SHA-256 of complete PDF bytes | 2026-09-07 | Last updated date where stated; otherwise first publication | GMP/GDP guidance | 2026-11-09 | EMA | 2026-09-07 | GMP / pharmaceutical manufacturing | 2024-08-01 | 3 | Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products Legal effective date: 10/09/2026 English (EN) (173.93 KB - PDF) First published: 01/08/2024 Last updated: 07/09/2026 View | Guidance on Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products | Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products | false | View row | ||||||
| 45 | Infarmed | 2026-11-19 | Document unavailable; no content hash or change determination possible | Unknown | — | — | — | 2026-09-04 | Circular issue date stated on official document page | Infarmed:087/CD/550.20.001:2026 | Recall circular | 2026-11-09 | Infarmed | 2026-11-03 | Suspensão de fabrico e recolha de soluções estéreis do fabricante Sterisets Manufacturing, SA | 2026-11-03 | 1.0 | Official document page metadata verified; the attachment could not be downloaded. Document content and changes are unknown. | Manufacturing suspension and recall of sterile solutions, as stated by the official notice title. Full document unavailable. | Suspensão de fabrico e recolha de soluções estéreis do fabricante Sterisets Manufacturing, SA | true | View row | |||||
| 46 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | TCI Co., Ltd BioCosme PABP BRANCH | c48d2e5458ef30bbb9fea43e1035463c570bbceb885d5b6560601c840e756136 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-02 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-06 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-06 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | TCI Co., Ltd BioCosme PABP BRANCH - GMP warning letter | false | View row | |||||
| 47 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Happy Farm Botanicals, Inc. | 24b112821657bc796aba99b576693538a393e4ff054f1edfd719c163db8c21a1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-01 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-08 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-08 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Happy Farm Botanicals, Inc. - GMP warning letter | false | View row | |||||
| 48 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Jabil Inc. | ae8530911c10ca8c649144d06061e5470d0a3f9c42a781579b2622a82a702486 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-08-27 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-01 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-01 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Jabil Inc. - GMP warning letter | false | View row | |||||
| 49 | FDA | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Fresenius Medical Care AG & Co. KGaA | 8320a869feec025ddf610f0d4236fccac464f08c195a4e0161764b5abca0983f | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-08-25 | Letter issue date | — | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-01 | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-01 | — | — | CGMP/Finished Pharmaceuticals/Adulterated | Fresenius Medical Care AG & Co. KGaA - GMP warning letter | false | View row | |||||
| 50 | EMA / EudraGMDP | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | New | Aculife Healthcare Private Limited | b8557b3becb5e1a77744504456c09c14b15812ec07db8616b15fb1788f462cdf | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-08-24 | Report issue date | GMP non-compliance report | 2026-11-09 | Malta Medicines Authority | — | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.4 Small volume liquids 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.5 Packaging 1.5.2 Secondary packaging | 2026-08-24 | — | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | The inspection resulted in a critical deficiency on inadequate cleaning validation as well as eight (8) major findings. These dealt with inadequate control of identification labels inside the manufacturing area, inadequate management of visual inspection activities, sterilized product passing through an area where un-sterilized bags were waiting to be autoclaved, inadequate container closure integrity testing and delayed action to correct this very long standing issue, process validation inadequacies, deficient complaint management, deficient management of aseptic process simulations as well as insufficient qualification of manufacturers and suppliers of critical starting materials and no reassurance that primary packaging materials for ophthalmic products were free from contamination. There were also 24 other deficiencies, in addition to the critical and major findings. All these observed deficiencies raise concerns that the approach to the manufacturing of sterile products is not adequately managing inherent risks pertaining to sterile processes and is not in line with applicable EU GMP requirements. As a result of this outcome, the Inspection Review Group (IRG) at the Malta Medicines Authority has met and decided that a Statement of Non-Compliance with the principles and guidelines of EU Good Manufacturing Practice is to be issued for the site. | MT/003NCR/2026 - Aculife Healthcare Private Limited | false | View row |
About this dataset
Official GMP regulatory documents with source links, document references, source-stated dates and revisions, capture timestamps and document change tracking. Refreshed 19 November 2026 with 416 document records.
What you can use it for
Researchers can compare document records using content hashes and change fields. Regulatory teams can find documents by agency, date, document type or product area. Analysts can review warning-letter categories and document source links.
Coverage
FDA: 235 warning letters, 11 draft guidance documents and 11 final guidance documents. EMA: 6 GMP/GDP guidance documents. EudraLex: 38 Volume 4 references. Infarmed: 47 recall circulars, 10 GMP/GDP quality circulars and 8 restriction-lifted circulars. EudraGMDP: 50 public GMP non-compliance reports. Publication dates span August 2008 to 18 November 2026, including older current reference documents. Recent regulatory records use a rolling two-year discovery window; this is a scoped sample, not an exhaustive regulatory archive.
Delivery options
How Jsonify collected this data
Nobody wrote a scraper for this. Someone described the data they wanted, in a sentence, and Jason, Jsonify's AI data engineer, took it from there.
The illustration shows this pipeline’s saved steps and published data.
This pipeline refreshes on demand.

paulh
@Jason I need this data: GMP guidance and warning letters from FDA, EMA, EudraLex and Infarmed, with document dates, source links and change-comparison fields. The published dataset contains 416 document records.
Look at europa.eu, infarmed.pt and fda.gov.

JasonApp
Pipeline steps:
- Sources
- Discover
- Organize
- Extract documents
- Changes
Done. 416 documents published as v4:
· Infarmed2026-11-19T18:05:28.740874+00:00
Natural Essentials, Inc. · FDA2026-11-19T18:05:28.740874+00:00
What Jason built
The pipeline itself, and the record of every version, repair and quality check since.
Data pipeline
- 01 · input
Verified Index
Optional verified official document index from an interrupted…
- 02 · input
Previous
Last published regulatory snapshot, used only for identity…
- 03 · sources
Sources
europa.eu, fda.gov, infarmed.pt
- 04
Sources
Prepare official regulatory sources and read the previous…
- 05 · fan out
Discover
Discover current documents in FDA, EMA, European Commission…
- 06
Organize
Deduplicate document identities and interleave source families…
- 07 · fan out
Extract documents
Retrieve documents or retain verified index metadata with…
- 08
Changes
Compare full document fingerprints with the last successfully…
- 09 · output
Main
Current official GMP regulatory documents with source…
416 documents · v4
Verified Index
InputOptional verified official document index from an interrupted refresh. Omit for normal live discovery; use an exact captured dataset revision for recovery.
Previous
InputLast published regulatory snapshot, used only for identity, first-seen dates and change comparisons.
Sources
StepPrepare official regulatory sources and read the previous published snapshot for change comparisons.
Per input record: Discover
Fan outDiscover current documents in FDA, EMA, European Commission and Infarmed official indexes.
Organize
StepDeduplicate document identities and interleave source families so bounded runs include balanced source coverage.
Per input record: Extract documents
Fan outRetrieve documents or retain verified index metadata with explicit unavailable status when the document cannot be acquired.
Changes
StepCompare full document fingerprints with the last successfully published snapshot and retain original first-seen dates.
Main
OutputCurrent official GMP regulatory documents with source traceability and changes since the last published snapshot.
Column explanations
source_url links to the official document page; document_pdf_url links to its PDF when available. document_id is the source reference; revision_number, publication_date and last_modified_date contain only source-stated values. first_seen_at preserves the earliest recorded observation; captured_at identifies this collection. content_hash fingerprints complete PDF bytes or normalized HTML text, as specified in content_hash_basis. change_type is new, revised or unchanged compared with the previous saved snapshot; unknown denotes an unavailable document. unavailable_document explicitly flags a failed document retrieval. Blank hashes are not evidence of unchanged content. change_basis and source_date_notes explain baseline and date limitations. agency, issuing_office, document_type, title, company, product_area and summary_or_violation_category describe each record.
Version history
- v4
Retain unavailable documents, including download timeouts, with verified metadata and unknown change status. Recover interrupted refreshes from a verified index while fetching documents again.
- v3
Improves document metadata processing so the refresh can continue after repeated processing errors.
- v2
Retains the unavailable Sterisets notice with verified source details, a blank content hash, unknown change status and an explicit unavailable-document flag so the other documents can refresh.
- v1
Added a reusable official-source refresh with document links, references, source dates, complete-document fingerprints and change tracking.
Repairs
When a source changes and a step fails, Jason's repair and its outcome are recorded here.
Quality checks
- v4Issues found
Full-table structural checks passed, but the Annex 1 document has a confirmed corrupted reference and omitted source-stated date. Source completeness remains only partially verified.
Limitations
Fourteen documents were unavailable at capture: 13 FDA warning letters and one Infarmed notice. They retain verified official metadata and source links, with blank hashes, unavailable_document=true and change_type=unknown. The 402 available documents establish the initial hash baseline; new means new to the hash baseline, not necessarily newly published. Later successful refreshes compare full-document hashes against the previous saved snapshot. Source dates and revision numbers remain blank where not stated. PDF hashes cover document bytes; HTML hashes cover normalized document text. This refresh reused the complete official index captured earlier on 19 November 2026 and retrieved document contents again. Refreshes are manual; no automatic schedule is enabled.
Ready to start?
Frequently asked questions
Is this sample data free to use?
How do I credit Jsonify?
Can I buy the full dataset?
How is that different from collecting my own?
What do Download and Customize do?
Does collecting my own cost anything?
What does a live feed for my team include?
I run a site this data was read from. What can I do?
Need something different?
Describe it. Get verified rows, kept current.